Cancer Research Landon Prizes for Basic and Translational Cancer Research AACR Conference on Molecular Diagnostics - 2008
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tsao, H.
Right arrow Articles by Haluska, F. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tsao, H.
Right arrow Articles by Haluska, F. G.
[Cancer Research 60, 1800-1804, April 1, 2000]
© 2000 American Association for Cancer Research

Advances in Brief

Relative Reciprocity of NRAS and PTEN/MMAC1 Alterations in Cutaneous Melanoma Cell Lines1

Hensin Tsao, Xue Zhang, Kianna Fowlkes and Frank G. Haluska2

Department of Dermatology (H. T.), Division of Hematology/Oncology (H. T., X. Z., K. F., F. G. H.), Massachusetts General Hospital and Dana-Farber/Partners CancerCare, Boston, Massachusetts 02114, and Department of Medical Genetics, China Medical University, Shenyang, People’s Republic of China (X. Z.)

Both inactivation of the tumor suppressor gene, PTEN/MMAC1, and oncogenic activation of RAS have been described in human cutaneous melanoma. In mice, activation of a RAS-containing pathway is a necessary step in the pathogenesis of murine melanomas. Because PTEN negatively regulates on the downstream effects of phosphatidylinositol-3-kinase (PI3-K), we hypothesized that the loss of PTEN/MMAC1 and the activation of RAS may be largely equivalent because RAS is a known positive upstream regulator of PI3-K. We expanded our previous survey of PTEN/MMAC1 mutations and analyzed the RAS status of 53 cutaneous melanoma cell lines, 18 glioma cell lines, and 17 uncultured cutaneous melanoma metastasis. Overall, 51% of the cell lines had alterations in either PTEN/MMAC1 or RAS. We found 16 cell lines (30%) with alterations in PTEN/MMAC1 and 11 cell lines (21%) with activating NRAS mutations; only 1 cell line had concurrent alterations in both genes. Moreover, glioma cell lines with a high frequency of PTEN/MMAC1 inactivation had no identifiable RAS alterations. Ectopic expression of PTEN in several cutaneous melanoma cell lines suppressed colony formation irrespective of PTEN/MMAC1 status; furthermore, PTEN expression in cell lines carrying activated RAS also suppressed colony formation. The relative reciprocity of PTEN/MMAC1 abrogation and NRAS activation suggests that the two genetic changes, in a subset of cutaneous melanomas, are functionally overlapping.




This article has been cited by other articles:


Home page
 FASEB J.Home page
M. Muller, M. Obeyesekere, G. B. Mills, and P. T. Ram
Network topology determines dynamics of the mammalian MAPK1,2 signaling network: bifan motif regulation of C-Raf and B-Raf isoforms by FGFR and MC1R
FASEB J, May 1, 2008; 22(5): 1393 - 1403.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
K. Iwanaga, Y. Yang, M. G. Raso, L. Ma, A. E. Hanna, N. Thilaganathan, S. Moghaddam, C. M. Evans, H. Li, W.-W. Cai, et al.
Pten Inactivation Accelerates Oncogenic K-ras-Initiated Tumorigenesis in a Mouse Model of Lung Cancer
Cancer Res., February 15, 2008; 68(4): 1119 - 1127.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
W. M. Lin, A. C. Baker, R. Beroukhim, W. Winckler, W. Feng, J. M. Marmion, E. Laine, H. Greulich, H. Tseng, C. Gates, et al.
Modeling Genomic Diversity and Tumor Dependency in Malignant Melanoma
Cancer Res., February 1, 2008; 68(3): 664 - 673.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
K. M. Vasudevan, R. Burikhanov, A. Goswami, and V. M. Rangnekar
Suppression of PTEN Expression Is Essential for Antiapoptosis and Cellular Transformation by Oncogenic Ras
Cancer Res., November 1, 2007; 67(21): 10343 - 10350.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
T. F. Gajewski
Failure at the Effector Phase: Immune Barriers at the Level of the Melanoma Tumor Microenvironment
Clin. Cancer Res., September 15, 2007; 13(18): 5256 - 5261.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
B. Stecca, C. Mas, V. Clement, M. Zbinden, R. Correa, V. Piguet, F. Beermann, and A. Ruiz i Altaba
Melanomas require HEDGEHOG-GLI signaling regulated by interactions between GLI1 and the RAS-MEK/AKT pathways
PNAS, April 3, 2007; 104(14): 5895 - 5900.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
A. J. Miller and M. C. Mihm Jr.
Melanoma.
N. Engl. J. Med., July 6, 2006; 355(1): 51 - 65.
[Full Text] [PDF]

Home page
 Cancer Res.Home page
C. Petti, A. Molla, C. Vegetti, S. Ferrone, A. Anichini, and M. Sensi
Coexpression of NRASQ61R and BRAFV600E in Human Melanoma Cells Activates Senescence and Increases Susceptibility to Cell-Mediated Cytotoxicity.
Cancer Res., July 1, 2006; 66(13): 6503 - 6511.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
F. G. Haluska, H. Tsao, H. Wu, F. S. Haluska, A. Lazar, and V. Goel
Genetic alterations in signaling pathways in melanoma.
Clin. Cancer Res., April 1, 2006; 12(7): 2301s - 2307s.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
K. T. Flaherty
Chemotherapy and targeted therapy combinations in advanced melanoma.
Clin. Cancer Res., April 1, 2006; 12(7): 2366s - 2370s.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
J. A. Curtin, J. Fridlyand, T. Kageshita, H. N. Patel, K. J. Busam, H. Kutzner, K.-H. Cho, S. Aiba, E.-B. Brocker, P. E. LeBoit, et al.
Distinct Sets of Genetic Alterations in Melanoma
N. Engl. J. Med., November 17, 2005; 353(20): 2135 - 2147.
[Abstract] [Full Text] [PDF]

Home page
 Ann. N. Y. Acad. Sci.Home page
K. S.M. SMALLEY and M. HERLYN
Targeting Intracellular Signaling Pathways as a Novel Strategy in Melanoma Therapeutics
Ann. N.Y. Acad. Sci., November 1, 2005; 1059(1): 16 - 25.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. Biol.Home page
N. Bardeesy, M. Kim, J. Xu, R.-S. Kim, Q. Shen, M. W. Bosenberg, W. H. Wong, and L. Chin
Role of Epidermal Growth Factor Receptor Signaling in RAS-Driven Melanoma
Mol. Cell. Biol., May 15, 2005; 25(10): 4176 - 4188.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
M. M. Schuierer, F. Bataille, S. Hagan, W. Kolch, and A.-K. Bosserhoff
Reduction in Raf Kinase Inhibitor Protein Expression Is Associated with Increased Ras-Extracellular Signal-Regulated Kinase Signaling in Melanoma Cell Lines
Cancer Res., August 1, 2004; 64(15): 5186 - 5192.
[Abstract] [Full Text] [PDF]

Home page
 Genes Dev.Home page
J.-H. Mao, M. D. To, J. Perez-Losada, D. Wu, R. Del Rosario, and A. Balmain
Mutually exclusive mutations of the Pten and ras pathways in skin tumor progression
Genes & Dev., August 1, 2004; 18(15): 1800 - 1805.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
C. Wellbrock, L. Ogilvie, D. Hedley, M. Karasarides, J. Martin, D. Niculescu-Duvaz, C. J. Springer, and R. Marais
V599EB-RAF is an Oncogene in Melanocytes
Cancer Res., April 1, 2004; 64(7): 2338 - 2342.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
F. Cruz III, B. P. Rubin, D. Wilson, A. Town, A. Schroeder, A. Haley, T. Bainbridge, M. C. Heinrich, and C. L. Corless
Absence of BRAF and NRAS Mutations in Uveal Melanoma
Cancer Res., September 15, 2003; 63(18): 5761 - 5766.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
B. Govindarajan, X. Bai, C. Cohen, H. Zhong, S. Kilroy, G. Louis, M. Moses, and J. L Arbiser
Malignant Transformation of Melanocytes to Melanoma by Constitutive Activation of Mitogen-activated Protein Kinase Kinase (MAPKK) Signaling
J. Biol. Chem., March 7, 2003; 278(11): 9790 - 9795.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
M. S. Brose, P. Volpe, M. Feldman, M. Kumar, I. Rishi, R. Gerrero, E. Einhorn, M. Herlyn, J. Minna, A. Nicholson, et al.
BRAF and RAS Mutations in Human Lung Cancer and Melanoma
Cancer Res., December 1, 2002; 62(23): 6997 - 7000.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
C. Cohen, A. Zavala-Pompa, J. H. Sequeira, M. Shoji, D. G. Sexton, G. Cotsonis, F. Cerimele, B. Govindarajan, N. Macaron, and J. L. Arbiser
Mitogen-actived Protein Kinase Activation Is an Early Event in Melanoma Progression
Clin. Cancer Res., December 1, 2002; 8(12): 3728 - 3733.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2000 by the American Association for Cancer Research.